Blood test may predict bleeding risk in hemophilia a patients on emicizumab

NCT ID NCT04472169

Ongoing Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether measuring the amount of emicizumab in the blood can help predict bleeding risk in people with severe hemophilia A. Researchers will follow 100 adults and children who are already taking emicizumab and track any bleeding events over about a year. The goal is to see if drug levels measured by a special lab test can identify who is at higher risk for bleeds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emicizumab
What this could lead to: If successful, this could lead to a blood test that helps doctors adjust emicizumab dosing to better prevent bleeding in people with severe hemophilia A.
What could go wrong: This is an observational study, not a treatment trial. It may find no clear link between drug levels and bleeding risk, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Show contact details

Locations

CHU de Caen

Caen, France
Institut Coeur-Poumon, Pôle d'Hématologie-Transfusion, CHU

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.